表紙
市場調查報告書
商品編碼
998432

單株抗體的全球市場:各原材料類型(嵌合體,人,人體化,及老鼠),製做類型(體外,體內),適應症,終端用戶的預測(到2025年)- COVID-19累積的影響

Monoclonal Antibodies Market Research Report by Source Type, by Production Type, by Indication, by End-User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日期: | 出版商: 360iResearch LLP | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球單株抗體的市場規模,預計從2020年的896億5,258萬美元,擴大至2025年末為1,536億9,339萬美元。

COVID-19是影響幾乎全部產業的無與倫比的世界公共衛生緊急事件,在預測期間內預計帶給產業的成長長期性的影響。目前進行的調查擴大了框架,以確保包括潛在的COVID-19問題和發展途徑。 本報告提供有關COVID-19的見解,其中考慮了消費者行為和需求的變化,購買方式,供應鏈的新路由,當前市場力量的動態以及政府的重要介入等COVID-19對市場的影響相關洞察。

本報告提供全球單株抗體市場的相關調查,市場機會和課題,成長及阻礙因素,COVID-19累積的影響,各原材料類型、製做類型、適應症、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 序文

  • 調查目的
  • 市場區隔和涵蓋範圍
  • 調查期間
  • 貨幣和價格
  • 語言
  • 規定事項
  • 利害關係者

第2章 調查方法

  • 調查流程
    • 定義:調查目的
    • 決策:調查計劃
    • 準備:調查設備
    • 收集:資料來源
    • 分析:資料的解釋
    • 制定:資料檢驗
    • 公開:調查報告
    • 重複:報告的更新
  • 調查的實行
    • 開始:調查流程
    • 製作計劃:調查計劃
    • 實施實行:調查
    • 檢驗:發現與分析
    • 出版物:調查報告
  • 調查成果

第3章 摘要整理

  • 市場展望
  • 各終端用戶市場展望
  • 各適應症市場展望
  • 各製做類型市場展望
  • 各原材料類型市場展望
  • 各地區市場的展望
  • 其他競爭公司預測

第4章 市場概要

  • COVID-19累積的影響

第5章 市場洞察

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特的五力分析

第6章 各原材料類型市場

  • 嵌合體
  • 人體化
  • 老鼠

第7章 各製做類型市場

  • 體外
  • 體內

第8章 各適應症市場

  • 自體免疫疾病
  • 癌症
  • 感染疾病
  • 發炎性疾病
  • 微生物性疾病

第9章 各終端用戶市場

  • 醫院
  • 研究機關

第10章 南北美洲市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第12章 歐洲,中東、非洲市場

  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併、收購
    • 協定,合作,及夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 評估,認識,擴大

第14章 企業簡介

  • Abbott Laboratories
  • AbbVie, Inc
  • AbGenomics
  • ADC Therapeutics
  • ALMAC Group
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Idec Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GenScript Biotech Corporation
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi S.A.
  • Seagen Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Thermo Fisher Scientific, Inc

第15章 附錄

  • 討論指南
  • 許可證和價格
目錄
Product Code: MRR-ED54C46E8B32

The Global Monoclonal Antibodies Market size was estimated at USD 89.65 Billion in 2020 and expected to reach USD 100.30 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 12.22% to reach USD 179.06 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Source Type, the Monoclonal Antibodies Market was studied across Chimeric, Human, Humanized, and Murine.

Based on Production Type, the Monoclonal Antibodies Market was studied across In Vitro and In Vivo.

Based on Indication, the Monoclonal Antibodies Market was studied across Autoimmune Diseases, Cancer, Infectious Diseases, Inflammatory Diseases, and Microbial Diseases.

Based on End-User, the Monoclonal Antibodies Market was studied across Hospitals and Research Institutes.

Based on Geography, the Monoclonal Antibodies Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Monoclonal Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Monoclonal Antibodies Market, including Abbott Laboratories, AbbVie, Inc, AbGenomics, ADC Therapeutics, ALMAC Group, Amgen Inc., Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, Biogen Idec Inc., Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Novo Nordisk A/S, Pfizer Inc, Sanofi S.A., Seagen Inc., Shanghai Junshi Biosciences Co., Ltd., and Thermo Fisher Scientific, Inc.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Monoclonal Antibodies Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Monoclonal Antibodies Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Monoclonal Antibodies Market?
  • 4. What is the competitive strategic window for opportunities in the Global Monoclonal Antibodies Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Monoclonal Antibodies Market?
  • 6. What is the market share of the leading vendors in the Global Monoclonal Antibodies Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Monoclonal Antibodies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. End-User Outlook
  • 3.4. Indication Outlook
  • 3.5. Production Type Outlook
  • 3.6. Source Type Outlook
  • 3.7. Geography Outlook
  • 3.8. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
      • 5.1.1.2. Rising incidence of cancer and other chronic diseases
      • 5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
    • 5.1.2. Restraints
      • 5.1.2.1. Pricing of therapeutic mAbs are expensive
    • 5.1.3. Opportunities
      • 5.1.3.1. High adoption rate in developing countries
      • 5.1.3.2. Substantial increase in the number of approvals per year
    • 5.1.4. Challenges
      • 5.1.4.1. Limitation in current manufacturing and purification processes (risk of contamination) affect production capacity and led to increasing cost
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Monoclonal Antibodies Market, by Source Type

  • 6.1. Introduction
  • 6.2. Chimeric
  • 6.3. Human
  • 6.4. Humanized
  • 6.5. Murine

7. Monoclonal Antibodies Market, by Production Type

  • 7.1. Introduction
  • 7.2. In Vitro
  • 7.3. In Vivo

8. Monoclonal Antibodies Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cancer
  • 8.4. Infectious Diseases
  • 8.5. Inflammatory Diseases
  • 8.6. Microbial Diseases

9. Monoclonal Antibodies Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes

10. Americas Monoclonal Antibodies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States
    • 10.6.1. California
    • 10.6.2. Florida
    • 10.6.3. Illinois
    • 10.6.4. New York
    • 10.6.5. Ohio
    • 10.6.6. Pennsylvania
    • 10.6.7. Texas

11. Asia-Pacific Monoclonal Antibodies Market

  • 11.1. Introduction
  • 11.2. China
  • 11.3. India
  • 11.4. Indonesia
  • 11.5. Japan
  • 11.6. Malaysia
  • 11.7. Philippines
  • 11.8. South Korea
  • 11.9. Thailand

12. Europe, Middle East & Africa Monoclonal Antibodies Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Quadrant
  • 13.4. Market Share Analysis, By Company
  • 13.5. Competitive Scenario
    • 13.5.1. Merger & Acquisition
    • 13.5.2. Agreement, Collaboration, & Partnership
    • 13.5.3. New Product Launch & Enhancement
    • 13.5.4. Investment & Funding
    • 13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. Abbott Laboratories
  • 14.2. AbbVie, Inc
  • 14.3. AbGenomics
  • 14.4. ADC Therapeutics
  • 14.5. ALMAC Group
  • 14.6. Amgen Inc.
  • 14.7. Astellas Pharma Inc
  • 14.8. AstraZeneca PLC
  • 14.9. Bayer AG
  • 14.10. Biogen Idec Inc.
  • 14.11. Bristol Myers Squibb
  • 14.12. Daiichi Sankyo Company, Limited
  • 14.13. Eli Lilly and Company
  • 14.14. F. Hoffmann-La Roche AG
  • 14.15. GenScript Biotech Corporation
  • 14.16. GlaxoSmithKline PLC
  • 14.17. Johnson & Johnson Services, Inc.
  • 14.18. Merck & Co., Inc.
  • 14.19. Mylan N.V.
  • 14.20. Novartis International AG
  • 14.21. Novo Nordisk A/S
  • 14.22. Pfizer Inc
  • 14.23. Sanofi S.A.
  • 14.24. Seagen Inc.
  • 14.25. Shanghai Junshi Biosciences Co., Ltd.
  • 14.26. Thermo Fisher Scientific, Inc

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing
  • 15.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2020 (USD BILLION)
  • FIGURE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2020 (USD BILLION)
  • FIGURE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
  • FIGURE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET: MARKET DYNAMICS
  • FIGURE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2020 VS 2026 (%)
  • FIGURE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2020 VS 2026 (USD BILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2026
  • FIGURE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, 2018-2026 (USD BILLION)
  • FIGURE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, 2018-2026 (USD BILLION)
  • FIGURE 15. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, 2018-2026 (USD BILLION)
  • FIGURE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, 2018-2026 (USD BILLION)
  • FIGURE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2020 VS 2026 (%)
  • FIGURE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2020 VS 2026 (USD BILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2026
  • FIGURE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, 2018-2026 (USD BILLION)
  • FIGURE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, 2018-2026 (USD BILLION)
  • FIGURE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
  • FIGURE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD BILLION)
  • FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2026
  • FIGURE 30. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 31. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 32. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, 2018-2026 (USD BILLION)
  • FIGURE 33. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 34. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 36. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 37. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 38. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, 2018-2026 (USD BILLION)
  • FIGURE 39. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 40. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2020 VS 2026 (%)
  • FIGURE 41. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2020 VS 2026 (USD BILLION)
  • FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2026
  • FIGURE 43. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, 2018-2026 (USD BILLION)
  • FIGURE 44. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 45. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2026 (USD BILLION)
  • FIGURE 46. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 47. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 48. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 49. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 50. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 51. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 52. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 53. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 54. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 55. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 56. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 57. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 58. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 59. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 60. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 61. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 62. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 63. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 64. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 65. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 66. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 67. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 68. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 69. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 70. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 71. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 72. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 73. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 74. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 75. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 76. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 77. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 78. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 79. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 80. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 81. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 82. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 83. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 84. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 85. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 86. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 87. GLOBAL MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX
  • FIGURE 88. GLOBAL MONOCLONAL ANTIBODIES MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 89. GLOBAL MONOCLONAL ANTIBODIES MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 90. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MONOCLONAL ANTIBODIES MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL MONOCLONAL ANTIBODIES MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 15. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 20. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 21. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 22. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 23. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 24. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 25. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 26. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 27. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 28. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 29. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 30. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 31. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 32. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 33. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 34. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 35. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 36. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 37. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 38. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 39. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 40. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 41. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 42. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 43. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 44. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 45. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 46. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 47. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 48. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 49. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 50. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 51. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 52. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 53. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 54. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 55. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 56. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 57. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 58. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 59. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 60. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 61. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 62. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 63. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 64. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 65. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 66. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 67. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 68. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 69. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 70. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 71. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 72. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 73. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 74. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 75. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 76. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 77. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 78. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 79. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 80. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 81. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 82. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 83. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 84. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 85. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 86. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 87. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 88. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 89. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 90. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 91. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 92. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 93. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 94. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 95. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 96. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 97. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 98. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 99. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 100. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 101. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 102. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 103. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 104. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 105. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 106. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 107. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 108. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 109. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 110. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 116. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 117. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 118. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 119. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 120. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 121. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 122. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 123. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 124. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 125. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 126. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 127. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 128. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 129. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 130. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 131. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 132. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 133. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 134. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 135. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 136. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 137. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 138. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 139. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 140. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 141. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 142. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 143. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 144. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 145. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 146. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 147. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 148. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 149. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 150. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 151. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 152. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 153. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 154. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 155. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 156. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 157. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 158. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 159. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 160. GLOBAL MONOCLONAL ANTIBODIES MARKET: SCORES
  • TABLE 161. GLOBAL MONOCLONAL ANTIBODIES MARKET: BUSINESS STRATEGY
  • TABLE 162. GLOBAL MONOCLONAL ANTIBODIES MARKET: PRODUCT SATISFACTION
  • TABLE 163. GLOBAL MONOCLONAL ANTIBODIES MARKET: RANKING
  • TABLE 164. GLOBAL MONOCLONAL ANTIBODIES MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 165. GLOBAL MONOCLONAL ANTIBODIES MARKET: SHARE, BY COMPANY, 2020
  • TABLE 166. GLOBAL MONOCLONAL ANTIBODIES MARKET: MERGER & ACQUISITION
  • TABLE 167. GLOBAL MONOCLONAL ANTIBODIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 168. GLOBAL MONOCLONAL ANTIBODIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 169. GLOBAL MONOCLONAL ANTIBODIES MARKET: INVESTMENT & FUNDING
  • TABLE 170. GLOBAL MONOCLONAL ANTIBODIES MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 171. GLOBAL MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING
  • TABLE 172. GLOBAL MONOCLONAL ANTIBODIES MARKET: CONTACT DETAILS